EPO Patent Publication EP4629997A1: ASBT Inhibitors for Renal Disease Treatment

ChangeBridge: EPO Bulletin - Pharma (A61K)

Published March 18th, 2026

Detected March 25th, 2026

Summary

The European Patent Office has published patent application EP4629997A1 concerning ASBT inhibitors for the treatment of renal diseases, filed by Albireo AB. The publication date is March 18, 2026.

View original document View source feed page

What changed

The European Patent Office (EPO) has published patent application EP4629997A1, detailing "ASBT inhibitors for the treatment of renal diseases." The application was filed by Albireo AB and lists Erik Lindström, Ellen Strängberg, Jan Hengstler, and Ahmed Ghallab as inventors. The publication date is March 18, 2026, and it covers various designated states within Europe.

This publication represents a new patent application and does not impose immediate compliance obligations on regulated entities. However, it signifies potential future developments in pharmaceutical treatments for renal diseases, which may be relevant for drug manufacturers and pharmaceutical companies monitoring innovation in this therapeutic area. No specific compliance actions or deadlines are associated with this patent publication.

Source document (simplified)

← EPO Patent Bulletin

ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES

Publication EP4629997A1 Kind: A1 Mar 18, 2026

Applicants

Albireo AB

Inventors

LINDSTRÖM, Erik, STRÄNGBERG, Ellen, HENGSTLER, Jan, GHALLAB, Ahmed

IPC Classifications

A61K 31/4995 20060101AFI20240614BHEP A61K 31/554 20060101ALI20240614BHEP A61K 31/7042 20060101ALI20240614BHEP A61P 13/12 20060101ALI20240614BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →